盘中异动 | 药明生物盘中上涨5%,报于86.85港元
2022年1月11日10时43分,药明生物(HK02269)盘中上涨5%,报于86.85港元,成交额达6.52亿港元,换手率达到0.16%。
1月10日讯,据港交所文件:1月4日,摩根大通对药明生物(02269.HK)的多头头寸从4.94%增加到5.0%。
12月24日,第一上海:维持药明生物(02269)“买入”评级,目标价108.7港元。12月7日,中金:港股医药板块进入底部区域,配置价值持续提升。12月7日,大摩:予药明生物(02269)“增持”评级,目标价175港元。
最新的财务数据显示,公司于2021年2季度,营业收入44.07亿人民币,净利润18.83亿人民币;营业收入同比增加126.67%,毛利润同比增加190.8%,净利润同比增加157.67%。
盈立趋势长盈模型最近一次交易信号,2022年1月4日出现观望信号,触发价格为82.85港元(信号仅供参考)。
uSMART智能写手的信息、数据均来自媒体公开报道,智能写手不能保证其完全准确,内容仅供参考,不构成投资建议。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.